Home Newsfeeds Piper Sandler Maintains Overweight on Chevron, Lowers Price Target to $199

Piper Sandler Maintains Overweight on Chevron, Lowers Price Target to $199

Piper Sandler analyst Ryan Todd maintains Chevron (NYSE:CVX) with a Overweight and lowers the price target from $206 to $199.

byBenzinga Newsdesk

December 19, 2022

1 minute read

Piper Sandler analyst Ryan Todd maintains Chevron (NYSE:CVX) with a Overweight and lowers the price target from $206 to $199.

What’s Going On With Clover Health Investments Stock?

By Ryan Gustafson

August 29, 4:17 PM

Clover Health Investments, Corp. (NASDAQ: CLOV) shares are trading higher Tuesday.

CLOV

Lineage Cell Therapeutics Announces OpRegen Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit

By Benzinga Newsdesk

May 6, 8:04 AM

BCVA gains of +5.5 letters at 24 months in Cohort 4 patients (n=10)BCVA gains of +7.4 letters among Cohort 4 patients with extensive OpRegen bleb coverage of the GA lesion (n=5)Maintenance or increases in external

LCTX

Fastenal Q4 EPS $0.43 Beats $0.42 Estimate, Sales $1.70B Beat $1.68B Estimate

By Benzinga Newsdesk

January 19, 7:50 AM

Fastenal (NASDAQ:FAST) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.42 by 2.38 percent. This is a 7.5 percent increase over earnings of $0.40 per share from the same

FAST

RingCentral On Track To Retire $1.6B Debt In FY26 With Strong FCF Focus: Analyst Forecasts

By Nabaparna Bhattacharya

August 8, 3:45 PM

Needham analyst Ryan Koontz reiterated a Buy rating on RingCentral, Inc (NYSE: RNG),

RNG

Piper Sandler Maintains Overweight on Chevron, Lowers Price Target to $199

Related Posts

What’s Going On With Clover Health Investments Stock?

Lineage Cell Therapeutics Announces OpRegen Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit

Fastenal Q4 EPS $0.43 Beats $0.42 Estimate, Sales $1.70B Beat $1.68B Estimate

RingCentral On Track To Retire $1.6B Debt In FY26 With Strong FCF Focus: Analyst Forecasts